Press Release 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Collaboration
Investegate announcements from 4Bio Capital, 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
Press Release 4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics 4 January 2022 LONDON & BOSTON - 4BIO Capital ("4BIO" or "the Group"), an international venture capital
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
04/20/2021 | 09:00am EDT
Send by mail :
Message :
20 April 2021
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. (“Code Bio” or the ”Company”), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alongside UPMC Enterprises, with participation from CureDuchenne Ventures, The JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.